Didik Indiarso

Didik Indiarso

Auto-generated profile, based on publicly available information

Didik Indiarso

Gastroentero-Hepatology Division, Department of Internal Medicine, Dr Kariadi Hospital, Indonesia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Journal of Biomedicine and Translational Research
Verified
Journal Article
Open access
PDF file
DIDidik Indiarso
Didik Indiarso
APAgung Prasetyo
Agung Prasetyo
HHHirlan Hirlan
Hirlan Hirlan
HPHery Djagat Purnomo
Hery Djagat Purnomo
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) has been the most common cause of chronic liver disease worldwide. In NAFLD, elevated Plasminogen Activator Inhibitor-1 (PAI-1) is associated with risk factors for thrombosis and hypercoagulable state.Objective: This study explored the relationship between NAFLD as an independent factor for increasing PAI-1 in the presence of metabolic syndrome and insulin resistance.Methods: This observational study used a cross-sectional design with 80 subjects including 40 patients with NAFLD and 40 without NAFLD at dr. Kariadi Semarang who met the inclusion and exclusion criteria. Measurement of plasma PAI-1 levels was done using ELISA method.Results: A total of 80 patients were included. In the case group, based on abdominal ultrasound, NAFLD was mostly found in the mild category (86%), while the rest were moderate (10%), and severe (4%). Only 25% were found in the Simple Steatosis category, and 75% were suspected of having NASH (NAS = 3-4) and NASH (NAS > 5). There was a significant difference between plasma PAI-1 level and the incidence of NAFLD (p = 0.011). The mean PAI-1 level between the three NAFLD severity categories also shown a significant difference (p = 0.032).Conclusion: There is an increase in PAI-1 levels in patients with NAFLD. PAI-1 levels have an independent effect on the degree of liver fibrosis in patients with NAFLD.

15 December 2022 in Journal of Biomedicine and Translational Research
Verified
Journal Article
Open access
PDF file
HPHery Djagat Purnomo
Hery Djagat Purnomo
HPHeru Prabowo
Heru Prabowo
CPCecilia Oktaria Permatadewi
Cecilia Oktaria Permatadewi
HHHesti Triwahyu Hutami
Hesti Triwahyu Hutami
DIDidik Indiarso
Didik Indiarso
HHHirlan Hirlan
Hirlan Hirlan
Background: Stress-related mucosal disease (SRMD) frequently develops in critically ill patients, increasing mortality and length of intensive care unit (ICU) stay. There is limited data on stress ulcer prophylaxis (SUP) on critically ill patients in Indonesia. Objective: Methods: This is a retrospective cohort study of patients admitted to the ICU from January 1, 2015, to December 31, 2017. The subjects were all ICU patients who used proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) as SUP therapy. Results: A total of 315 patients were included, and mean age was 48 years. Approximately 55.2% were women, and 62.8% of patients were admitted to ICU following high-risk surgery. PPI was given to 187 patients (59.4%) and H2RA to 128 patients (40.6%), with an average usage for 5 days. The incidence of SRMD was 15.9% (n = 50), and mean length of stay in the ICU was 6 days. Gender, age, duration of SUP, and ICU length of stay of the PPI and H2RA groups were not statistically different (p > 0.05) and did not affect the GI event (p > 0.05). The use of rational SUP was 98.4%. Major American Society of Health-System Pharmacists (ASHP) risk factor criterion was ventilator use (86.8%), while the minor ASHP criterion was anticoagulant therapy (22.2%). The incidence of GI event was significantly lower in PPI groups than H2RA groups (p < 0.05). Conclusions: The use of SUP is rational with an average use of 5 days. PPI are superior to H2RA for SRMD prophylaxis.